Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00750 (PLA)
 16,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In vivo a powerful triad of endothelial secretogogues regulates thrombo-resistance and vascular tone. In physio-pathological circumstances stimulation of endothelial receptors (purinergic, muscarinic, kinin) releases prostacyclin (PGI2), nitric oxide (NO) and tissue plasminogen activator (t-PA) in a coupled manner. Alliance between them occurs at level of protection against deposition of thrombi over the vascular wall. Activation of fibrinolysis by t-PA through generation of plasmin is complemented with multifactorial desactivation of platelets by PGI2 and a selective inhibition of release of plasminogen activator inhibitor-1 (PAI-1) from platelets by NO. This concerted action of the triad leads to increase in anti-thrombotic and thrombolytic potentials. Administrated separately t-PA (or streptokinase) and PGI2 (or iloprost) produce unwanted effects such as "paradoxic thrombogenesis" or "rebound activation of platelets", respectively. It is because they are missing a natural ally. On the other hand, endothelial regulation of vascular tone depends on NO, exclusively. Only exogenous PGI2 is hypotensive, and even then it does not synergize with NO. In vitro all types of interactions between PGI2 and NO occur. For instance, synergism--in platelets, addition--in vascular smooth muscle and antagonism--in macrophages. Activity of arachidonate cyclooxygenase is claimed to be either stimulated or inhibited by NO. A transfer of conclusions from in vitro data to living systems must be very cautious.
Pol J Pharmacol
PMID:Endothelial nitric oxide, prostacyclin (PGI2) and tissue plasminogen activator (t-PA): alliance or neutrality? 886 42

The following factors of fibrinolysis: tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor-1 (PAI-1) play an important role in patients after trauma. Their possible mechanisms in head-injured patients remain unknown. We studied the maintenance of those markers of fibrinolysis in the plasma and cerebrospinal fluid of 19 patients after severe head injury (initially GCS less than 8 p) without intracranial haematoma. We measured changes of the level of t-PA antigen and PAI-1 activity in days 0-3, 4-6 and later. T-PA antigen level in the plasma was higher than normally (4-8 ng/ml). T-Pa was present in the cerebrospinal fluid, but its level reached only 30% of the plasma level. In the days following injury the t-PA antigen level decreased. The PAI-1 activity in the plasma was normal (0-15 IU/ml). However, its activity in csf was high and reached, 80% of the plasma level and systematically increase in the following days particularly in patients who died. PAI-1 activity can be connected with the presence of damaged brain tissue and its necrosis and its increase can be a marker of poor prognosis.
Neurol Neurochir Pol
PMID:[Tissue plasminogen activator (T-PA) and tissue plasminogen activator inhibitor (PAI-1) in patients after head injury]. 896 77

We examined various hemostatic abnormalities in 395 patients with disseminated intravascular coagulation (DIC), in 177 patients in a Pre-DIC stage, and in 99 patients who did not exhibit DIC. Pre-DIC was defined as the condition at least one week before the onset of DIC. The differences in activated partial thromboplastin time (APTT), FDP, prothrombin time (PT) ratio, fibrinogen, and platelet count between DIC and Non-DIC patients were significant, but there were no significant differences in these parameters between Pre-DIC and Non-DIC patients. Plasma levels of fibrin-D-dimer, thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), soluble fibrin monomer (sFM), prothrombin activated peptide F1 + 2 (F1 + 2), thrombomodulin (TM), tissue type plasminogen activator (t-PA), and PA inhibitor (PAI-I) in DIC patients were significantly higher than levels in Non-DIC patients. However, only TAT, sFM and PAI-I values in the Pre-DIC patients were significantly higher than the values in the Non-DIC patients. Almost all the hemostatic molecular markers examined had high sensitivity for DIC, but only TAT and PPIC had high sensitivity for Pre-DIC. Specificity for DIC was also high with TAT, sFM, and F1 + 2. Early diagnosis and early treatment are important in DIC; we believe that it is possible to predict Pre-DIC by assessing values for the combination of hemostatic molecular markers.
Pol J Pharmacol
PMID:Diagnosis of pre-disseminated intravascular coagulation stage with hemostatic molecular markers. The Mie DIC Study Group. 911 56

Radiologic contrast media may influence processes of hemostasis resulting in increased thrombotic or bleeding tendency. A number of clinical case reports suggest that the use of nonionic contrast media is associated with thrombotic complications. In vitro studies have indicated that nonionic contrast media may induce generation of thrombin in blood whereas ionic contrast agents do not show such an effect. Not much is known about the effects of contrast media on the coagulation and fibrinolytic systems in vivo. The aim of this study was to evaluate the systemic effects of markers for activation of fibrinolysis with a nonionic contrast medium (Iopromid/Ultravist-300/Schering AG) and ionic contrast medium (Uropolinum, Polfa) in 82 patients undergoing angiography. We measured tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI), using COA-SET, t-PA and COA-TEST PAI (Chromogenix). Fibrinogen concentration and euglobulin lysis time (ELT) were also estimated. Both contrast agents caused a significant decrease in fibrinogen concentrations. A marked difference was seen for PAI activity. A statistically significant increase was seen in the Iopromid group and no statistically significant rise was seen in the Uropolinum group. t-PA activity remained virtually unchanged in both groups. ELT has been significantly prolonged in patients who received Iopromid but not in those who received Uropolinum. It is likely that nonionic contrast medium could release PAI from platelets and endothelial cells. The changes in fibrinolysis may result from endothelial cell dysfunction.
Pol J Pharmacol
PMID:Effect of nonionic and ionic contrast media on fibrinolysis in patients undergoing angiography. 911 70

A patient, aged 34, with a relapse of Behcet's disease (BD) showed laboratory features of enhanced coagulation activation without any symptoms of arterial or venous thrombosis. Elevated levels of thrombin-antithrombin III complexes (TAT), prothrombin fragments 1 + 2 (F1 + 2), associated with impairement of fibrinolysis were found. Total fibrinolytic activity, measured on fibrin plates, plasma concentration of tissue-type plasminogen activator (tPA:Ag) and plasmin-alpha 2-antiplasmin complexes (PAP) were low, whereas plasminogen activator inhibitor 1 concentration (PAI-1:Ag) was elevated in comparison with normal values. There intravenous 500 mg doses of cyclophosphamide, given on day 0, 7 and 50, resulted in a marked clinical improvement. This was accompanied by the normalization of augmented thrombin generation and increased fibrinolytic activity. This is the first report to show prothrombotic tendency in a relapse of Behcet disease and beneficial effect of cyclophosphamide therapy on haemostatic abnormalities. A degree of activation of coagulative and fibrinolytic system seems to be of importance in the pathogenesis of Behcet's disease, and monitoring of hemostatic parameters could be helpful in clinical assessment.
Pol Arch Med Wewn 1996 Sep
PMID:[Subclinical pro-thrombotic state in a relapse of Behcet's disease--case report]. 912 17

The aim of work was to study whether activity and antigen level of tissue plasminogen activator (t-PA) and activity of plasminogen activator inhibitor (PAI-1) were related to severity and extensiveness of vascular lesions in peripheral obliterative atherosclerotic disease (POAD). The study group consisted of 25 patients in II (13), III (10) and IV (2) degrees of disease acc. to Fontaine'a. In the blood t-PA activity and antigen and activity of PAI-1 were determined. In the patients with more severe POAD higher t-PA antigen and increased t-PA complexed with PAI-1 were observed. In patients with unisegmental POAD twice t-PA activity than in patients with polysegmental atherosclerotic lesions was detected.
Pol Merkur Lekarski 1996 Oct
PMID:[Tissue plasminogen activator and inhibitor and the severity and extensiveness of vascular lesions in peripheral atherosclerosis of the legs]. 915 32

The aim of study was the evaluation of tissue plasminogen activator (t-PA) and its inhibitor (PAI-1) in the II type diabetes on the base of the common fibrinolytic system tests as euglobulin lysis time (ELT) and the concentration of fibrin/fibrinogen products (FDP). The studies were performed in 21 outpatients suffering of II type diabetes aged 38-65 (median 56.0) years treated with diet and sulphonylcarbamide derivates. The control group contained 18 healthy persons aged 33-65 (median 42.0) years. In the blood the following determinations were performed: antigen of t-PA and PAI-1, ELT and FDP. In the blood of patients with II type diabetes increased. t-PA Ag and PAI-1 Ag concentrations were observed.
Pol Merkur Lekarski 1997 Jan
PMID:[Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes]. 929 93

In the 20 patients with prostatic carcinoma (PC) and the 18 with benign prostatic hyperplasia (BPH) the level of tissue type plasminogen activator (t-PA:Ag) was examined. As a compared group consisted of 24 healthy volunteers. In the urine of examined patients with PC and BPH and control the t-PA:Ag was absent or present only in trace amounts. We concluded that the t-PA:Ag in the urine of patients with PC can not be as a marker in the diagnosis of prostatic diseases especially in the prostatic carcinoma.
Pol Merkur Lekarski 1997 Apr
PMID:[Tissue plasminogen activator in urine of patients with prostatic carcinoma and benign prostatic hyperplasia]. 937 62

In urine of 25 patients with bladder carcinoma the antigen of tissue type plasminogen activator (t-PA) was assessed. The level of t-PA was much higher in patients with bladder carcinoma in comparison with a control group. We also analyzed the level of t-PA between patients with superficial and invasive bladder carcinoma the level of t-PA was higher. In conclusion, there is t-PA in urine of patients with bladder carcinoma and its level is correlated with staging of neoplasm.
Pol Merkur Lekarski 1997 Jun
PMID:[Tissue type plasminogen activator antigen in urine of patients with bladder cancer]. 942 24

Plasminogen activators and inhibitors regulate a variety of physiological and pathological processes involved in tissue morphogenesis, cell differentiation, migration, cancer cell invasion and metastasis. Several reports have shown the decrease of fibrinolytic activity in the blood of cancer patients. In this study we measured the concentrations of tissue plasminogen activator (t-PA), urokinase plasminogen activator (u-PA), activity of plasminogen activator inhibitor type 1 (PAI-1) and euglobulin lysis time (ELT) in the blood of 20 men aged 42-75 years old with planoepitheliale larynx carcinoma, and 10 healthy persons in similar age. In this study the mean values of t-PA, u-PA concentrations, PAI-1 activity and ELT in the blood of patients with larynx carcinoma were similar to the examination results of healthy persons, but 40% of our cancer patients have increased activity of PAI-1.
Otolaryngol Pol 1995
PMID:[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]. 945 29


<< Previous 1 2 3 4 5 6 Next >>